MetaVia (MTVA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
A virtual Special Meeting of Stockholders is scheduled for September 18, 2024, to vote on two key proposals related to the issuance of common stock underlying certain warrants and potential adjournment to solicit more proxies if needed.
The Board unanimously recommends voting in favor of both proposals, emphasizing the importance of shareholder participation.
The meeting will be held online, and shareholders can vote electronically or by proxy in advance.
Voting matters and shareholder proposals
Proposal 1 seeks approval, per Nasdaq Listing Rule 5635(d), for the issuance of up to 12,849,878 shares of common stock upon exercise of Series A, Series B, and Placement Agent Warrants, exceeding 20% of outstanding shares.
Proposal 2 authorizes adjournment of the meeting to solicit additional proxies if there are insufficient votes for Proposal 1.
Only shareholders of record as of August 16, 2024, are entitled to vote, with certain shares issued in the recent private placement excluded from voting on these proposals.
Abstentions count as votes against, and broker non-votes are not permitted as both proposals are non-routine.
Board of directors and corporate governance
The Board of Directors, led by Chair Andrew I. Koven, is actively soliciting proxies and recommends voting for both proposals.
None of the directors or executive officers have substantial interests in the matters up for vote.
Latest events from MetaVia
- Promising obesity and MASH therapies advance with strong early data and major market potential.MTVA
Investor presentation26 Mar 2026 - Strong clinical progress and improved financials position the pipeline for key 2026 milestones.MTVA
Q4 202526 Mar 2026 - DA-1726 and vanoglipel advance in clinical trials, with key data and partnerships expected this year.MTVA
Emerging Growth Virtual Conference25 Feb 2026 - Biotech seeks $6M via unit offering to fund clinical programs, with significant dilution risk.MTVA
Registration Filing12 Jan 2026 - Biotech seeks $12.8M via unit offering to fund MASH/obesity drug trials amid ongoing losses.MTVA
Registration Filing5 Jan 2026 - 14M shares registered for resale after private placement; biotech faces ongoing losses and key risks.MTVA
Registration Filing16 Dec 2025 - Key votes include director elections, a reverse stock split, and share issuance approval tied to Dong-A.MTVA
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, reverse split, and major share issuance.MTVA
Proxy Filing2 Dec 2025 - Approval sought for warrant share issuance and potential adjournment, with major dilution possible.MTVA
Proxy Filing2 Dec 2025